Many journals with a significant readership in the Two-Thirds World struggle to maintain a strong subscriber base, and Tropical Doctor is no exception. The Royal Society of Medicine Press publishes Tropical Doctor on a non-profit making basis, and discriminates positively in favour of those working in the developing countries by offering subscriptions at about 60% of the rate for the developed world. Despite this, the current developing world subscription level of £30 is still beyond the reach of many and last year we lost 137 subscribers, mostly in Africa. Please write to us if you are in the latter group, and let us know what you feel about our policy. We receive some grants to assist us in providing subscriptions to those for whom foreign currency is a major problem, or for whom the current subscription level is simply too expensive.
Last year a significant development took place in India. Panther Publishers obtained sponsorship from Nicholas Piramal India Ltd and are now distributing 15000 copies of Tropical Doctor in its entirety to Indian doctors. We warmly welcome our new Indian readers. Indian authors make a very strong contribution to published papers in Tropical Doctor and we are delighted that at long last we have a circulation in India which reflects the wealth of clinical expertise that India contributes to world medicine. At a stroke Tropical Doctor readership has increased by 1000%. Long may it continue.
Michael Jones

Editor
Substandard and counterfeit drugs in developing countries
The paper by Rirnoy, Moshi and Massele in the current issue (p. 15) is very topical and adds to the increasing evidence of widespread availability of sub-standard quality drugs in developing countries.
When such quality issues were first noticed and commented on, poor quality drugs were considered synonymous with counterfeit or, more colloquially, 'fake' drugs. High profile cases were brought to public attention where substitution of toxic compounds for pharmaceuticals resulted in deaths (paracetamol syrup in Bangladesh). It was tacitly assumed that drug products, Tropical Doctor January 2002, 32 which contained inappropriate amounts of active ingredient, were counterfeit and manufactured with the purpose of increasing profit from their sales. Counterfeiting has been precisely defined by the World Health Organization as requiring fraudulent intent. This removes the drug quality problem from the scientific and medical field to the legal arena and offers little prospect of improvement of the situation. More recently, as more objective and less anecdotal data become available, a consensus has emerged that an appreciable proportion of drug preparations available in developing countries are sub-standard, i.e. they do not conform to the pharmacopoeial standards applied in more developed countries. This noncompliance may indeed be a result of counterfeiting but may also be due to drug decomposition caused by the high humidity and temperature of storage, or the lack of adequate quality control and quality assurance in manufacture.
Much effort in identifying and controlling such substandard products has aimed at identifying counterfeiting and has depended on visual inspection of the dosage form in order to detect differences from the authentic material. Suspect products can then be tested by simple chemical separative techniques such as thin-layer chromatography to check if the appropriate active ingredient is present in roughly the correct amount. Relatively recently, validated chemical analytical methods, both pharmacopoeial and chromatographic, have been used to determine the precise amount of active ingredient in medicines available to the general public in several developing countries. Overall, these investigations have shown that, while a high proportion of samples tested did not conform to pharamacopoeial standards in terms of quantity of drug present, relatively few showed the complete absence of active ingredient. The exception to this is a recent study carried out by Newton and co-workers on artemisinin products available in the market place in South-East Asia where visual examination of products coupled with a commercial kit testing system for the drug showed widespread use and sale of counterfeit products'.
The paper by Rimoy et al. takes this objective quantitative approach to quality further and is one of the few studies to investigate the amount of drug available from different dosage forms. Such an investigation goes beyond determining the amount of active ingredient present in a dosage form and highlights the situation where the correct amount is apparently inappropriately formulated leading to significantly lower blood concentrations. This supports the contention of other workers that lack of quality control of active content is a major cause of sub-standard drugs and extends this problem to include the characteristics (formulation) of "the finished product.
The effect of either inadequate drug formulation or content leads to a sub-therapeutic dose and the development of drug resistance of infectious agents. The consequences of this are obvious: (I) relatively cheap drugs will become ineffective; (2) the loss of such drugs will require new drugs development, which will be more expensive and will further disadvantage patients in developing countries; (3) selection of drug resistant
